The Role of Kidney in Glucose Homeostasis — SGLT2 Inhibitors, a New Approach in Diabetes Treatment

Vasileios Andrianesis; John Doupis


Expert Rev Clin Pharmacol. 2013;6(5):519-539. 

In This Article


SGLT2 inhibition is an innovative strategy for the management of type 2 diabetes. Apart from the main glucosuric effect, the improved glycemic control and the significant HbA1c reduction, SGLT2 inhibitors present also additional beneficial effects in patients with type 2 diabetes such as body weight and systolic blood pressure reduction and HDL increase. Canagliflozin is the first SGLT2 inhibitor approved bythe FDA, and dapagliflozin is the first one approved in Europe from the EMA. Many other SGLT2 inhibitors are currently under investigation.

Empagliflozin has completed the Phase III registration trials and its new drug application was submitted to the FDA in March 2013 for approval.[112] In Japan, ipragliflozin has also completed its clinical program and its application for marketing approval has been submitted to the Ministry of Health, Labour and Welfare in Japanin March 13 too.[113] Other SGLT2 inhibitors currently under clinical development are summarized in Table 4 .

It seems that we have in our hands a new promising, potent and effective weapon for the fight against diabetes. Undoubtedly, further studies are necessary to better establish its position in our anti-diabetic armamentarium.